Evidence That Intermittent Structured Treatment Interruption, but Not Immunization with ALVAC-HIV vCP1452, Promotes Host Control of HIV Replication: The Results of AIDS Clinical Trials Group 5068

Autor: National Institute of Allergy and Infectious Diseases-AIDS Clinical Trials Group 5068 Protocol Team, Jacobson, Jeffrey M., Bucy, R. Pat, Spritzler, John, Saag, Michael S., Eron, Joseph J., Coombs, Robert W., Wang, Rui, Fox, Lawrence, Johnson, Victoria A., Cu-Uvin, Susan, Cohn, Susan E., Mildvan, Donna, O'Neill, Dorothy, Janik, Jennifer, Purdue, Lynette, O'Connor, Deborah K., Di Vita, Christine, Frank, Ian

Publikováno v: The Journal of Infectious Diseases, 2006 Sep 01. 194(5), 623-632.

Externí odkaz: https://www.jstor.org/stable/30085855

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy.

Autor: Li JZ; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America., Chapman B; Harvard School of Public Health, Boston, Massachusetts, United States of America., Charlebois P; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America., Hofmann O; Harvard School of Public Health, Boston, Massachusetts, United States of America., Weiner B; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America., Porter AJ; Harvard School of Public Health, Boston, Massachusetts, United States of America., Samuel R; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America; Department of Virology, University of KwaZulu-Natal, National Health Laboratory Service, Durban, South Africa., Vardhanabhuti S; Harvard School of Public Health, Boston, Massachusetts, United States of America., Zheng L; Harvard School of Public Health, Boston, Massachusetts, United States of America., Eron J; Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, United States of America., Taiwo B; Division of Infectious Diseases, Northwestern University, Chicago, Illinois, United States of America., Zody MC; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America., Henn MR; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America., Kuritzkes DR; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America., Hide W; Harvard School of Public Health, Boston, Massachusetts, United States of America., Wilson CC; University of Colorado., Berzins BI; Northwestern University., Acosta EP; University of Alabama at Birmingham., Bastow B; ACTG Operations Center, Social & Scientific Systems, Inc., Kim PS; National Institute of Allergy and Infectious Diseases., Read SW; National Institute of Allergy and Infectious Diseases., Janik J; Frontier Science & Technology Research Foundation., Meres DS; National Institute of Allergy and Infectious Diseases., Lederman MM; Case Western Reserve University., Mong-Kryspin L; Ohio State University., Shaw KE; Henry Ford Hospital CRS., Zimmerman LG; University of Colorado CRS., Leavitt R; Merck., De La Rosa G; Tibotec., Jennings A; ACTG Operations Center.

Publikováno v: PloS one [PLoS One] 2014 Mar 06; Vol. 9 (3), pp. e90485. Date of Electronic Publication: 2014 Mar 06 (Print Publication: 2014).